Annual reportSep 2026
Sep 2026 · Appointment 31 Aug - Board approved FY26 annual report, AGM notice for 28 Sept 2026, and appointed auditors and advisors.
Source: Nse
Galaxy Medicare Ltd. (GML)
SME CapPharma stocks · SME cap · NSE
Galaxy Medicare Ltd. operates in Medical Consumables, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals20 Oct 2026 · screener
Latest result01 Jun, 07:53 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags04 Oct 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
74BullishMACD + · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 56
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
GMLD candles · FIT view-4.8%Latest close ₹19.00 on 2026-10-21
Bar
+4.1%
RSI
59
MACD hist
0.22
52W pos
45%
2026-10-21O ₹18.25H ₹19.00L ₹18.10C ₹19.00Vol 12,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
GMLNifty PharmaNifty 500
- GML
- +8.0%
- Nifty 500
- -5.6%
- Nifty Pharma
- -0.7%
- Vs Nifty 500
- +13.6 pp
Chart stats
21 Oct 2026- From 52W high
- -64.8%
- 52W range position
- 10%
- ATR (14)
- 4.0%
- Volume vs 20D
- 0.96x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹16.1 - ₹19.1
₹54
₹15.2 - ₹54
₹0.8
Latest completed session
20-session average
49.3% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED67
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Bullish74
Price trend and sector-relative-strength timing.
Valuation
Legacy model+81.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence71
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Pending dataYoY comparison unavailable - result verdict pending data
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹21.3 Cr | NDF | +13.6% |
| EBITDA | ₹1.4 Cr | NDF | -52.1% |
| Operating margin | 6.4% | NDF | -883 bps |
| PAT | ₹1.4 Cr | NDF | -30.7% |
| PAT margin | 6.6% | NDF | -420 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 8.30
- P/B
- 0.71
- EV/EBITDA
- 6.80
- Market Cap
- 28.90Cr
Profitability
- ROE
- 10.80%
- ROCE
- 13.90%
- ROA
- 7.01%
- Dividend Y
- 4.12%
Growth (CAGR)
- Revenue 5Y
- 7.00%
- EPS 5Y
- 36.00%
- Revenue 3Y
- 9.00%
- EPS 3Y
- 59.00%
Balance Sheet
- Debt/Equity
- 0.10
- Interest Coverage
- 15.43×
- Altman Z
- 4.19
- Book Value
- 26.60
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 4/5
- OCF
- 1.77 Cr
- EPS TTM
- 2.25
Shareholding
- Promoter Hold
- 73.36%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 44%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 21.3+13.6% vs prev
Net Profit
₹ CrLatest: 1.4-30.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bullish setupTrend is constructive — long-term uptrend intact. RSI 59.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 roughly flat — short-term momentum stalled.
- RSI(14) at 59 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 20% off 52W high · 25% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
76
RS percentile
Stage 1 Base / Transition
1M return
+12.1%
3M return
-1.6%
6M return
+18.8%
1Y return
-
RS 1D
0
RS 20D
+35
Sector rank
#1
Industry rank
#5
Stage evidence
- Price is within 5.1% of the 30-week proxy.
- The 30-week proxy changed -2.2% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price above
200-DMA
price above
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
222 observations
21 Oct 2026Value 57.93+0.66%
RS vs Nifty 50058
Valuation & peers
U-Score 67 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 67 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · UNDERVALUEDValuation30/30
Growth19/25
Quality2/20
Balance Sheet15/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
-8
Raw sum
67
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
67/100 · legacy band UNDERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 81.2%.
- Valuation contributes 30/30 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
8.3
PB
0.7
EV/EBITDA
6.8
ROE
10.8%
ROCE
13.9%
FCF Yield
—
Debt/Equity
0.1
MoS
+81.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
67
Previous: 67
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+81.2%
Previous: +81.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
68
68
68
68
68
68
68
68
68
68
67
67
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹36.7
+48.2% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹101.25
+81.2% MoS
PEG
0.18
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
OSELDEVICE
SME
Osel Devices Ltd.
Medical Devices
match 125
60
21.1
18.7%
+53%
UNDERVALUED
VILINBIO
SME
VILIN BIO MED LTD.
Medical Devices
match 123
31
44.6
7.5%
+7%
OVERVALUED
INFLUX
SME
Influx Healthtech Ltd.
Medical Devices
match 123
27
31.8
19.0%
-296%
OVERVALUED
POLYMED
Large
Poly Medicure Limited
Medical Devices
match 117
32
50.1
9.0%
-11%
WATCHLIST
NURECA
Small
Nureca Limited
Medical Devices
match 116
23
65.9
1.1%
-7143%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Galaxy Medicare Ltd. operates in Medical Consumables, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
71Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 66th percentile of the scored universe and 54th percentile within Pharma. Main check: financial discipline is weak at 50/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
66th percentile
overall median 67 · Pharma: 54th pctile, median 70 · SME: 85th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
50
watch · capital discipline
Results
55
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 73%.
- ▸Promoter pledge is zero.
- ▸4 years of positive FCF.
- ▸Debt/equity is 0.10.
Trust risks
- ▸ROCE trend is -3%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Galaxy Medicare Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportSep 2026
Sep 2026 · Outcome of Board Meeting 31 Aug - Board approved FY26 annual report, AGM on 28 Sep 2026, and appointed internal auditor and IR agency.
Source: Nse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.